|
|
|
Volumn 47, Issue 1212, 2005, Pages 55-56
|
|
Pegaptanib sodium (Macugen) for macular degeneration
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BENZOPORPHYRIN DERIVATIVE;
BEVACIZUMAB;
PEGAPTANIB;
RANIBIZUMAB;
VASCULOTROPIN;
VASCULOTROPIN 165;
VASCULOTROPIN INHIBITOR;
APTAMER;
OLIGONUCLEOTIDE;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG COST;
DRUG DOSE REGIMEN;
DRUG ELIMINATION;
DRUG EXCRETION;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG MECHANISM;
ENDOPHTHALMITIS;
EYE INFLAMMATION;
HUMAN;
MAXIMUM ALLOWABLE CONCENTRATION;
NONHUMAN;
PHOTODYNAMIC THERAPY;
RETINA DETACHMENT;
RETINA MACULA DEGENERATION;
SHORT SURVEY;
THROMBOEMBOLISM;
TRAUMATIC CATARACT;
VISUAL ACUITY;
VISUAL IMPAIRMENT;
VITREOUS FLOATERS;
VITREOUS OPACITY;
ARTICLE;
INJECTION;
VISUAL DISORDER;
VITREOUS BODY;
APTAMERS, NUCLEOTIDE;
HUMANS;
INJECTIONS;
MACULAR DEGENERATION;
OLIGONUCLEOTIDES;
VISION DISORDERS;
VITREOUS BODY;
|
|
EID: 22344455695
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (11)
|
|
References (3)
|
